Marrow Therapeutics Unveils $173M for ‘Trojan Horse’ Delivery of Blood Disorder Drugs
Sickle cell disease and beta thalassemia are the startup’s lead indications. While gene therapies are available for both blood disorders, Marrow executives say manufacturing and do...